Retatrutide is a novel triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously
In a clinical trial with 2,519 patients, Zepbound (tirzepatide) was taken at doses of 5 mg, 10 mg, and 15 mg over a 72-week period, with an additional 958 people receiving a placebo
Worked really well for me Works amazing
However, it is entirely appropriate and indeed advisable to raise questions about retatrutide with your GP or a specialist, particularly if you are considering enrolling in a clinical trial, have seen media coverage of the drug, or are managing conditions such as obesity or type 2 diabetes for which it may eventually become relevant
How Effective Is Semaglutide for Weight Loss in Non-Diabetics